## Multimedia Appendix 1

## Table of Contents

Table S1. Inclusion and exclusion criteria of the DigiToms study	2
Table S2. Study participants' baseline characteristics.	3
Table S3. DMT treatment allocation	5
Figure S1. Konectom™ app tests for cognitive and manual dexterity function	6
Figure S2. Summary schedule of Konectom <sup>™</sup> app tests for cognition, dexterity, and gait and posture	7
Figure S3. EDSS distribution	8
Figure S4. Process for selection and analysis of sensor-derived measures	9

	Inclusion criteria	Exclusion criteria
People with MS	<ul> <li>Aged 18-64 years</li> <li>Diagnosis of MS according to 2017 revised McDonald criteria</li> <li>EDSS score ≤6.0</li> </ul>	<ul> <li>Severe ongoing psychiatric condition, including depression</li> <li>Change of DMT or psychotropic treatment in the last month</li> <li>Clinically significant addiction</li> <li>Recent acute relapse or disability worsening (&lt;1 month)</li> <li>Steroid course in the previous month</li> <li>Neuropsychological testing in the previous year</li> </ul>
Healthy participants	<ul> <li>Recruited from a center- owned database</li> <li>Participants were considered healthy if they were not suffering from injuries that could affect walking and turning, or fine motor function</li> <li>Aged 18-64</li> <li>Matched to MS patient sample for age, gender, and level of education</li> </ul>	<ul> <li>Severe ongoing psychiatric condition, including depression</li> <li>Any clinically significant neurological disorder</li> <li>Any psychotropic therapy consumption</li> <li>Clinically significant addiction</li> <li>Previous participation in other cognitive study using the same tests</li> <li>Developmental learning disabilities</li> </ul>

 Table S1. Inclusion and exclusion criteria of the DigiToms study.

DMT disease-modifying therapy. EDSS Expanded Disability Status Scale. MS multiple sclerosis.

Characteristic	People with MS (n=85)	Healthy Participants (n=68)	P value
<b>Age</b> (year), median (min, max)	44.0 (20.0, 62.0)	40.5 (20.0, 62.0)	.3018ª
Gender, n (%)			
Female	70 (82.4)	57 (83.8)	.8098 <sup>b</sup>
Male	15 (17.6)	11 (16.2)	
Body mass index (kg/m <sup>2</sup> ), median (min, max)	23.7 (16.6, 44.6)	23.5 (16.8, 36.5)	.9269ª
MS type, N (%)			
PPMS/PRMS/SPMS	4 (4.7)	NA	NA
RRMS	81 (95.3)	NA	NA
<b>Disease duration</b> (year), median (min, max)	8 (0,37)	NA	NA
Number of relapses last 12 months, median (min, max)	0.0 (0.0, 5.0)	NA	NA
Education Level, <sup>f</sup> N (%)			
ISCED <3	14 (16.5)	9 (13.2)	.9374 <sup>b</sup>
ISCED 3	16 (18.8)	12 (17.6)	
ISCED 4-6	38 (44.7)	32 (47.1)	
ISCED >6	17 (20.0)	15 (22.1)	
Job status, N (%)			
Unemployed	18 (21.2)	6 (8.8)	.0057 <sup>b</sup>
Part-time job	22 (25.9)	9 (13.2)	
Full-time job	45 (52.9)	53 (77.9)	
Dominant hand, N (%)			
Left	9 (10.6)	5 (7.4)	.4904 <sup>b</sup>
Right	76 (89.4)	63 (92.6)	
Ambidextrous	0 (0.0)	0 (0.0)	
EDSS, median (min, max)	2.0 (0.0, 4.5)	NA	NA
9HPT dominant hand (seconds), <sup>d</sup> mean (SD)	21.4 (6.7)	18.0 (2.0)	<.0001ª

 Table S2. Study participants' baseline characteristics.

<b>9HPT</b> nondominant Hand (seconds), <sup>d</sup> mean (SD)	22.2 (4.4)	18.6 (2.0)	<.0001ª
<b>T25FW</b> (seconds), <sup>e</sup> mean (SD)	4.5 (0.8)	4.0 (0.5)	<.0001ª
Daily Walk test (meters), mean (SD)	495.0 (102.3)	556.1(77.7)	.0002ª
<b>SDMT</b> (number of correct responses), <sup>c</sup> median (min, max)	58 (29, 85)	65 (41, 85)	.0002ª
<b>BVMT</b> <sup>c</sup> , median (Q1, Q3)	31 (6, 36)	32 (10, 36)	.1155ª
<b>FVLT</b> ⁰, median (Q1, Q3)	68 (34, 77)	67.5 (38, 77)	.6445ª

<sup>a</sup>Wilcoxon test.

<sup>b</sup>Chi-square test.

<sup>c</sup>Performed either at V1 or V2, depending on randomization.

<sup>d</sup>Average time to complete the test from both attempts.

<sup>e</sup>Average time to complete the test from both attempts (seconds).

fISCED <3: No baccalaureate = did not complete upper secondary education, ISCED 3: Baccalaureate = completed upper secondary education, ISCED 4-6: Secondary education short (≥ Baccalaureate +2) = post-secondary tertiary education < master level, ISCED >6: Secondary education long (≥ Baccalaureate

+5) = master level and above.

*BVMT* Brief Visuospatial Memory Test. *EDSS* Expanded Disability Status Scale. *FVLT* French Verbal Learning Test. *ISCED* International Standard Classification of Education. *MS* multiple sclerosis. *PPMS* primary progressive multiple sclerosis. *PRMS* progressive relapsing multiple sclerosis. *RRMS* relapsingremitting multiple sclerosis. *SPMS* secondary-progressive multiple sclerosis. *SDMT* Symbol Digit Modalities Test.

DMT	Number of patients
Natalizumab	58
Ocrelizumab	15
Other DMTs <sup>a</sup>	12

## Table S3. DMT treatment allocation


Excludes patients who were lost to follow-up (three people with MS).

<sup>a</sup>Included teriflunomide, dimethyl fumarate, fingolimod, glatiramer acetate, azathioprine, methotrexate,

cyclophosphamide.

*DMT* disease-modifying therapy.


Figure S1. Konectom<sup>™</sup> app tests for cognitive and manual dexterity function. A



В




С



Konectom<sup>™</sup> app interface: (A) Cognitive Processing Speed test; (B) Drawing test; (C) Pinching test.

Figure S2. Summary schedule of Konectom<sup>™</sup> app tests for cognition, dexterity, and gait and posture.


Test Type	Test name	
Experience Sampling	.0 0 0	Mood scale
		MSIS-29 Multiple Sclerosis Impact Scale
Cognition		Symbols & Numbers Cognitive Processing Speed
Fine Motor	۲	Pinch Balloons Pinching Test
	<b>)</b>	Draw a Shape Drawing Test
Gait & Posture		Balance & U-turn Static Balance & U-Turn Test
		Daily Walk 6 Minute Walk Test



## Figure S3. EDSS distribution.

EDSS Expanded Disability Status Scale.

Figure S4. Process for selection and analysis of sensor-derived measures.



SDM sensor-derived measures.